APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preclinical Assets

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Preclinical Assets Market Analysis and Forecast 2026-2032

17 January 2026198 pages

Choose your research edition.

Industry ResearchPreclinical Assets Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Preclinical Assets Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Preclinical Assets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preclinical Assets Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Preclinical Assets Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Preclinical Assets market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Preclinical Assets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Preclinical Assets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Preclinical Assets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Preclinical Assets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Preclinical Assets include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Preclinical Assets, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Preclinical Assets, also provides the revenue of main regions and countries. Of the upcoming market potential for Preclinical Assets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Preclinical Assets revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Preclinical Assets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Preclinical Assets revenue, projected growth trends, production technology, application and end-user industry.

Preclinical Assets Segment by Company

Eurofins Scientific

Viroclinics Xplore

SGS

Intertek Group

AmplifyBio

IQVIA

ICON plc

Medpace

Pharmatest Services

PPD

Crown Bioscience

Comparative Biosciences

TCG Lifesciences

Domainex

Absorption Systems

Preclinical Assets Segment by Type

Bioanalysis and DMPK Studies

Toxicology Testing

Compound Management

Safety Pharmacology

Others

Preclinical Assets Segment by Application

Biopharmaceutical Companies

Government Institutes

Research institutes

Others

Preclinical Assets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Assets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preclinical Assets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Assets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Preclinical Assets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Preclinical Assets company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Preclinical Assets revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Preclinical Assets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bioanalysis and DMPK Studies Major Player Table 3. Toxicology Testing Major Player Table 4. Compound Management Major Player Table 5. Safety Pharmacology Major Player Table 6. Others Major Player Table 7. Global Preclinical Assets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Biopharmaceutical Companies Major Player Table 9. Government Institutes Major Player Table 10. Research institutes Major Player Table 11. Others Major Player Table 12. Preclinical Assets Industry Trends Table 13. Preclinical Assets Industry Drivers Table 14. Preclinical Assets Industry Opportunities and Challenges Table 15. Preclinical Assets Industry Restraints Table 16. Global Preclinical Assets Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Preclinical Assets Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Preclinical Assets Market Share by Region (2021-2026) Table 19. Global Preclinical Assets Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Preclinical Assets Market Share by Region (2027-2032) Table 21. Global Preclinical Assets Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Preclinical Assets Revenue Market Share by Players (2021-2026) Table 23. Global Preclinical Assets Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Preclinical Assets Key Players Headquarters & Area Served Table 25. Global Preclinical Assets Players, Product Type & Application Table 26. Global Preclinical Assets Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Preclinical Assets by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Preclinical Assets Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Preclinical Assets Revenue Market Share by Type (2021-2026) Table 33. Global Preclinical Assets Revenue Market Share by Type (2027-2032) Table 34. Global Preclinical Assets Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Preclinical Assets Revenue Market Share by Application (2021-2026) Table 38. Global Preclinical Assets Revenue Market Share by Application (2027-2032) Table 39. Eurofins Scientific Company Information Table 40. Eurofins Scientific Business Overview Table 41. Eurofins Scientific Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Eurofins Scientific Preclinical Assets Product Portfolio Table 43. Eurofins Scientific Recent Development Table 44. Viroclinics Xplore Company Information Table 45. Viroclinics Xplore Business Overview Table 46. Viroclinics Xplore Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Viroclinics Xplore Preclinical Assets Product Portfolio Table 48. Viroclinics Xplore Recent Development Table 49. SGS Company Information Table 50. SGS Business Overview Table 51. SGS Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. SGS Preclinical Assets Product Portfolio Table 53. SGS Recent Development Table 54. Intertek Group Company Information Table 55. Intertek Group Business Overview Table 56. Intertek Group Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Intertek Group Preclinical Assets Product Portfolio Table 58. Intertek Group Recent Development Table 59. AmplifyBio Company Information Table 60. AmplifyBio Business Overview Table 61. AmplifyBio Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. AmplifyBio Preclinical Assets Product Portfolio Table 63. AmplifyBio Recent Development Table 64. IQVIA Company Information Table 65. IQVIA Business Overview Table 66. IQVIA Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. IQVIA Preclinical Assets Product Portfolio Table 68. IQVIA Recent Development Table 69. ICON plc Company Information Table 70. ICON plc Business Overview Table 71. ICON plc Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. ICON plc Preclinical Assets Product Portfolio Table 73. ICON plc Recent Development Table 74. Medpace Company Information Table 75. Medpace Business Overview Table 76. Medpace Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Medpace Preclinical Assets Product Portfolio Table 78. Medpace Recent Development Table 79. Pharmatest Services Company Information Table 80. Pharmatest Services Business Overview Table 81. Pharmatest Services Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Pharmatest Services Preclinical Assets Product Portfolio Table 83. Pharmatest Services Recent Development Table 84. PPD Company Information Table 85. PPD Business Overview Table 86. PPD Preclinical Assets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. PPD Preclinical Assets Product Portfolio Table 88. PPD Recent Development Table 89. Crown Bioscience Company Information Table 90. Crown Bioscience Business Overview Table 91. Crown Bioscience Preclinical Assets Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Crown Bioscience Preclinical Assets Product Portfolio Table 93. Crown Bioscience Recent Development Table 94. Comparative Biosciences Company Information Table 95. Comparative Biosciences Business Overview Table 96. Comparative Biosciences Preclinical Assets Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Comparative Biosciences Preclinical Assets Product Portfolio Table 98. Comparative Biosciences Recent Development Table 99. TCG Lifesciences Company Information Table 100. TCG Lifesciences Business Overview Table 101. TCG Lifesciences Preclinical Assets Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. TCG Lifesciences Preclinical Assets Product Portfolio Table 103. TCG Lifesciences Recent Development Table 104. Domainex Company Information Table 105. Domainex Business Overview Table 106. Domainex Preclinical Assets Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Domainex Preclinical Assets Product Portfolio Table 108. Domainex Recent Development Table 109. Absorption Systems Company Information Table 110. Absorption Systems Business Overview Table 111. Absorption Systems Preclinical Assets Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Absorption Systems Preclinical Assets Product Portfolio Table 113. Absorption Systems Recent Development Table 114. North America Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Preclinical Assets Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Preclinical Assets Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Preclinical Assets Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Preclinical Assets Revenue by Country (US$ Million) & (2027-2032) Table 128. China Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 129. China Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 130. China Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 131. China Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Preclinical Assets Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Preclinical Assets Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Preclinical Assets Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Preclinical Assets Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Preclinical Assets Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Preclinical Assets Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Preclinical Assets Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Preclinical Assets Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Preclinical Assets Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Preclinical Assets Image Figure 2. Global Preclinical Assets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preclinical Assets Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bioanalysis and DMPK Studies Image Figure 5. Toxicology Testing Image Figure 6. Compound Management Image Figure 7. Safety Pharmacology Image Figure 8. Others Image Figure 9. Global Preclinical Assets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Preclinical Assets Market Size Share 2021 VS 2025 VS 2032 Figure 11. Biopharmaceutical Companies Image Figure 12. Government Institutes Image Figure 13. Research institutes Image Figure 14. Others Image Figure 15. Global Preclinical Assets Market Size (US$ Million) & (2021-2032) Figure 16. Global Preclinical Assets Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Preclinical Assets Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Preclinical Assets Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Preclinical Assets Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Preclinical Assets Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Preclinical Assets Revenue Market Share by Type (2021-2032) Figure 23. Global Preclinical Assets Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Preclinical Assets Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Preclinical Assets Revenue Market Share by Application (2021-2032) Figure 26. North America Preclinical Assets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Preclinical Assets Revenue Share by Type (2021-2032) Figure 28. North America Preclinical Assets Revenue Share by Application (2021-2032) Figure 29. North America Preclinical Assets Revenue Share by Country (2021-2032) Figure 30. United States Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Preclinical Assets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Preclinical Assets Revenue Share by Type (2021-2032) Figure 35. Europe Preclinical Assets Revenue Share by Application (2021-2032) Figure 36. Europe Preclinical Assets Revenue Share by Country (2021-2032) Figure 37. Germany Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Preclinical Assets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Preclinical Assets Revenue Share by Type (2021-2032) Figure 47. China Preclinical Assets Revenue Share by Application (2021-2032) Figure 48. Asia Preclinical Assets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Preclinical Assets Revenue Share by Type (2021-2032) Figure 50. Asia Preclinical Assets Revenue Share by Application (2021-2032) Figure 51. Asia Preclinical Assets Revenue Share by Region (2021-2032) Figure 52. Japan Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Preclinical Assets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Preclinical Assets Revenue Share by Type (2021-2032) Figure 60. SAMEA Preclinical Assets Revenue Share by Application (2021-2032) Figure 61. SAMEA Preclinical Assets Revenue Share by Country (2021-2032) Figure 62. Brazil Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Preclinical Assets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Safety Pharmacology
  • Others
Applications
  • Biopharmaceutical Companies
  • Government Institutes
  • Research institutes
  • Others
Companies covered
  • Eurofins Scientific
  • Viroclinics Xplore
  • SGS
  • Intertek Group
  • AmplifyBio
  • IQVIA
  • ICON plc
  • Medpace
  • Pharmatest Services
  • PPD
  • Crown Bioscience
  • Comparative Biosciences
  • TCG Lifesciences
  • Domainex
  • Absorption Systems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Preclinical Assets Market by Type
  3. 1.2.1 Global Preclinical Assets Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bioanalysis and DMPK Studies
  5. 1.2.3 Toxicology Testing
  6. 1.2.4 Compound Management
  7. 1.2.5 Safety Pharmacology
  8. 1.2.6 Others
  9. 1.3 Preclinical Assets Market by Application
  10. 1.3.1 Global Preclinical Assets Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Biopharmaceutical Companies
  12. 1.3.3 Government Institutes
  13. 1.3.4 Research institutes
  14. 1.3.5 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Preclinical Assets Market Dynamics
  1. 2.1 Preclinical Assets Industry Trends
  2. 2.2 Preclinical Assets Industry Drivers
  3. 2.3 Preclinical Assets Industry Opportunities and Challenges
  4. 2.4 Preclinical Assets Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Preclinical Assets Market Perspective (2021-2032)
  2. 3.2 Global Preclinical Assets Growth Trends by Region
  3. 3.2.1 Global Preclinical Assets Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Preclinical Assets Market Size by Region (2021-2026)
  5. 3.2.3 Global Preclinical Assets Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Preclinical Assets Revenue by Players
  2. 4.1.1 Global Preclinical Assets Revenue by Players (2021-2026)
  3. 4.1.2 Global Preclinical Assets Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Preclinical Assets Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Preclinical Assets Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Preclinical Assets Key Players Headquarters & Area Served
  7. 4.4 Global Preclinical Assets Players, Product Type & Application
  8. 4.5 Global Preclinical Assets Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Preclinical Assets Market CR5 and HHI
  11. 4.6.3 2025 Preclinical Assets Tier 1, Tier 2, and Tier 3
5 Preclinical Assets Market Size by Type
  1. 5.1 Global Preclinical Assets Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Preclinical Assets Revenue by Type (2021-2032)
  3. 5.3 Global Preclinical Assets Revenue Market Share by Type (2021-2032)
6 Preclinical Assets Market Size by Application
  1. 6.1 Global Preclinical Assets Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Preclinical Assets Revenue by Application (2021-2032)
  3. 6.3 Global Preclinical Assets Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eurofins Scientific
  2. 7.1.1 Eurofins Scientific Company Information
  3. 7.1.2 Eurofins Scientific Business Overview
  4. 7.1.3 Eurofins Scientific Preclinical Assets Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eurofins Scientific Preclinical Assets Product Portfolio
  6. 7.1.5 Eurofins Scientific Recent Developments
  7. 7.2 Viroclinics Xplore
  8. 7.2.1 Viroclinics Xplore Company Information
  9. 7.2.2 Viroclinics Xplore Business Overview
  10. 7.2.3 Viroclinics Xplore Preclinical Assets Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Viroclinics Xplore Preclinical Assets Product Portfolio
  12. 7.2.5 Viroclinics Xplore Recent Developments
  13. 7.3 SGS
  14. 7.3.1 SGS Company Information
  15. 7.3.2 SGS Business Overview
  16. 7.3.3 SGS Preclinical Assets Revenue and Gross Margin (2021-2026)
  17. 7.3.4 SGS Preclinical Assets Product Portfolio
  18. 7.3.5 SGS Recent Developments
  19. 7.4 Intertek Group
  20. 7.4.1 Intertek Group Company Information
  21. 7.4.2 Intertek Group Business Overview
  22. 7.4.3 Intertek Group Preclinical Assets Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Intertek Group Preclinical Assets Product Portfolio
  24. 7.4.5 Intertek Group Recent Developments
  25. 7.5 AmplifyBio
  26. 7.5.1 AmplifyBio Company Information
  27. 7.5.2 AmplifyBio Business Overview
  28. 7.5.3 AmplifyBio Preclinical Assets Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AmplifyBio Preclinical Assets Product Portfolio
  30. 7.5.5 AmplifyBio Recent Developments
  31. 7.6 IQVIA
  32. 7.6.1 IQVIA Company Information
  33. 7.6.2 IQVIA Business Overview
  34. 7.6.3 IQVIA Preclinical Assets Revenue and Gross Margin (2021-2026)
  35. 7.6.4 IQVIA Preclinical Assets Product Portfolio
  36. 7.6.5 IQVIA Recent Developments
  37. 7.7 ICON plc
  38. 7.7.1 ICON plc Company Information
  39. 7.7.2 ICON plc Business Overview
  40. 7.7.3 ICON plc Preclinical Assets Revenue and Gross Margin (2021-2026)
  41. 7.7.4 ICON plc Preclinical Assets Product Portfolio
  42. 7.7.5 ICON plc Recent Developments
  43. 7.8 Medpace
  44. 7.8.1 Medpace Company Information
  45. 7.8.2 Medpace Business Overview
  46. 7.8.3 Medpace Preclinical Assets Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Medpace Preclinical Assets Product Portfolio
  48. 7.8.5 Medpace Recent Developments
  49. 7.9 Pharmatest Services
  50. 7.9.1 Pharmatest Services Company Information
  51. 7.9.2 Pharmatest Services Business Overview
  52. 7.9.3 Pharmatest Services Preclinical Assets Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pharmatest Services Preclinical Assets Product Portfolio
  54. 7.9.5 Pharmatest Services Recent Developments
  55. 7.10 PPD
  56. 7.10.1 PPD Company Information
  57. 7.10.2 PPD Business Overview
  58. 7.10.3 PPD Preclinical Assets Revenue and Gross Margin (2021-2026)
  59. 7.10.4 PPD Preclinical Assets Product Portfolio
  60. 7.10.5 PPD Recent Developments
  61. 7.11 Crown Bioscience
  62. 7.11.1 Crown Bioscience Company Information
  63. 7.11.2 Crown Bioscience Business Overview
  64. 7.11.3 Crown Bioscience Preclinical Assets Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Crown Bioscience Preclinical Assets Product Portfolio
  66. 7.11.5 Crown Bioscience Recent Developments
  67. 7.12 Comparative Biosciences
  68. 7.12.1 Comparative Biosciences Company Information
  69. 7.12.2 Comparative Biosciences Business Overview
  70. 7.12.3 Comparative Biosciences Preclinical Assets Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Comparative Biosciences Preclinical Assets Product Portfolio
  72. 7.12.5 Comparative Biosciences Recent Developments
  73. 7.13 TCG Lifesciences
  74. 7.13.1 TCG Lifesciences Company Information
  75. 7.13.2 TCG Lifesciences Business Overview
  76. 7.13.3 TCG Lifesciences Preclinical Assets Revenue and Gross Margin (2021-2026)
  77. 7.13.4 TCG Lifesciences Preclinical Assets Product Portfolio
  78. 7.13.5 TCG Lifesciences Recent Developments
  79. 7.14 Domainex
  80. 7.14.1 Domainex Company Information
  81. 7.14.2 Domainex Business Overview
  82. 7.14.3 Domainex Preclinical Assets Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Domainex Preclinical Assets Product Portfolio
  84. 7.14.5 Domainex Recent Developments
  85. 7.15 Absorption Systems
  86. 7.15.1 Absorption Systems Company Information
  87. 7.15.2 Absorption Systems Business Overview
  88. 7.15.3 Absorption Systems Preclinical Assets Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Absorption Systems Preclinical Assets Product Portfolio
  90. 7.15.5 Absorption Systems Recent Developments
8 North America
  1. 8.1 North America Preclinical Assets Revenue (2021-2032)
  2. 8.2 North America Preclinical Assets Revenue by Type (2021-2032)
  3. 8.2.1 North America Preclinical Assets Revenue by Type (2021-2026)
  4. 8.2.2 North America Preclinical Assets Revenue by Type (2027-2032)
  5. 8.3 North America Preclinical Assets Revenue Share by Type (2021-2032)
  6. 8.4 North America Preclinical Assets Revenue by Application (2021-2032)
  7. 8.4.1 North America Preclinical Assets Revenue by Application (2021-2026)
  8. 8.4.2 North America Preclinical Assets Revenue by Application (2027-2032)
  9. 8.5 North America Preclinical Assets Revenue Share by Application (2021-2032)
  10. 8.6 North America Preclinical Assets Revenue by Country
  11. 8.6.1 North America Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Preclinical Assets Revenue by Country (2021-2026)
  13. 8.6.3 North America Preclinical Assets Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Preclinical Assets Revenue (2021-2032)
  2. 9.2 Europe Preclinical Assets Revenue by Type (2021-2032)
  3. 9.2.1 Europe Preclinical Assets Revenue by Type (2021-2026)
  4. 9.2.2 Europe Preclinical Assets Revenue by Type (2027-2032)
  5. 9.3 Europe Preclinical Assets Revenue Share by Type (2021-2032)
  6. 9.4 Europe Preclinical Assets Revenue by Application (2021-2032)
  7. 9.4.1 Europe Preclinical Assets Revenue by Application (2021-2026)
  8. 9.4.2 Europe Preclinical Assets Revenue by Application (2027-2032)
  9. 9.5 Europe Preclinical Assets Revenue Share by Application (2021-2032)
  10. 9.6 Europe Preclinical Assets Revenue by Country
  11. 9.6.1 Europe Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Preclinical Assets Revenue by Country (2021-2026)
  13. 9.6.3 Europe Preclinical Assets Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Preclinical Assets Revenue (2021-2032)
  2. 10.2 China Preclinical Assets Revenue by Type (2021-2032)
  3. 10.2.1 China Preclinical Assets Revenue by Type (2021-2026)
  4. 10.2.2 China Preclinical Assets Revenue by Type (2027-2032)
  5. 10.3 China Preclinical Assets Revenue Share by Type (2021-2032)
  6. 10.4 China Preclinical Assets Revenue by Application (2021-2032)
  7. 10.4.1 China Preclinical Assets Revenue by Application (2021-2026)
  8. 10.4.2 China Preclinical Assets Revenue by Application (2027-2032)
  9. 10.5 China Preclinical Assets Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Preclinical Assets Revenue (2021-2032)
  2. 11.2 Asia Preclinical Assets Revenue by Type (2021-2032)
  3. 11.2.1 Asia Preclinical Assets Revenue by Type (2021-2026)
  4. 11.2.2 Asia Preclinical Assets Revenue by Type (2027-2032)
  5. 11.3 Asia Preclinical Assets Revenue Share by Type (2021-2032)
  6. 11.4 Asia Preclinical Assets Revenue by Application (2021-2032)
  7. 11.4.1 Asia Preclinical Assets Revenue by Application (2021-2026)
  8. 11.4.2 Asia Preclinical Assets Revenue by Application (2027-2032)
  9. 11.5 Asia Preclinical Assets Revenue Share by Application (2021-2032)
  10. 11.6 Asia Preclinical Assets Revenue by Country
  11. 11.6.1 Asia Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Preclinical Assets Revenue by Country (2021-2026)
  13. 11.6.3 Asia Preclinical Assets Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Preclinical Assets Revenue (2021-2032)
  2. 12.2 SAMEA Preclinical Assets Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Preclinical Assets Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Preclinical Assets Revenue by Type (2027-2032)
  5. 12.3 SAMEA Preclinical Assets Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Preclinical Assets Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Preclinical Assets Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Preclinical Assets Revenue by Application (2027-2032)
  9. 12.5 SAMEA Preclinical Assets Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Preclinical Assets Revenue by Country
  11. 12.6.1 SAMEA Preclinical Assets Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Preclinical Assets Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Preclinical Assets Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst